Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge and Kirkland & Ellis advises Baxter in connection with the acquisition of Gambro
Mandate

Vinge and Kirkland & Ellis advises Baxter in connection with the acquisition of Gambro

December 05, 2012

Vinge and Kirkland & Ellis advises the global medical technology company Baxter International Inc. (“Baxter”) in connection with the acquisition of Gambro AB for an enterprise value of SEK 26.5 billion. Closing of the transaction is subject to applicable competition law approvals and other customary closing conditions.

Vinge acted as local counsel for Baxter. The Vinge team included Johan Winnerblad (partner), Jonas Bergström and Jonas Johansson together with, among others, Nicolina Kindblom, Gustav Jönsson, Rime Dreber, Emma Lindelöf, Daniel Unger, Helena Höök and Evelina Tejle.

Related

Vinge has advised Vicore Pharma Holding AB (publ) in connection with its rights issue

 Vinge has advised Vicore Pharma Holding AB (publ) in connection with an oversubscribed rights issue of shares whereby Vicore receives issue proceeds of approximately SEK 782 million before deduction of transaction costs.
October 22, 2024

Vinge has advised Vicore Pharma Holding AB (publ) in connection with its directed share issue

 Vinge has advised Vicore Pharma Holding AB (publ) in connection with a directed share issue, whereby Vicore receives issue proceeds of approximately SEK 100 million before deduction of transaction costs.
October 22, 2024

Vinge has advised the Swedish state in connection with the reconstruction proceedings of SAS

 Vinge has advised the Swedish state in connection with the reconstruction proceedings of SAS. The proceedings, which included considerations regarding state aid approved by the European Commission, have among other things involved restructuring, debt write-downs as well as an investment by a consortium consisting of Castlelake, Air France-KLM, Lind Invest and the Danish state. In total, the investment amounted to approximately USD 1.2 billion in SAS, divided into USD 475 million in unlisted equity and USD 725 million in convertible debt.
October 21, 2024